Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2026)

Rigel Pharmaceuticals has reported Short term Debt for 4 years, with the latest figure at $29.9 million in Q1 2026.

• For the quarter ending Q1 2026, Short term Debt rose 101.59% year-over-year to $29.9 million; the trailing twelve-month figure through Mar 2026 stood at $29.9 million (up 101.59% YoY), and the FY2025 full-year result was $29.8 million, up 309.96% from the prior year.
• Short term Debt for Q1 2026 stood at $29.9 million, roughly flat from $29.8 million in the prior quarter.
• The five-year high for Short term Debt was $29.9 million in Q1 2026, with the low at $7.2 million in Q4 2023.
• Average Short term Debt over 4 years is $19.5 million, with a median of $18.6 million recorded in 2025.
• Peak annual rise in Short term Debt reached 309.96% in 2025, while the deepest fall reached 0.24% in 2025.
• Tracing RIGL's Short term Debt over 4 years: stood at $7.2 million in 2023, then grew by 0.59% to $7.3 million in 2024, then surged by 309.96% to $29.8 million in 2025, then grew by 0.18% to $29.9 million in 2026.
• The last three Short term Debt figures came in at $29.9 million (Q1 2026), $29.8 million (Q4 2025), and $29.8 million (Q3 2025), per Business Quant data.

Peer Comparison